Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

AM. Zeidan, P. Fenaux, M. Gobbi, J. Mayer, GJ. Roboz, J. Krauter, T. Robak, HM. Kantarjian, J. Novák, WW. Jedrzejczak, X. Thomas, M. Ojeda-Uribe, Y. Miyazaki, YH. Min, SP. Yeh, JM. Brandwein, L. Gercheva, J. Demeter, EA. Griffiths, KWL. Yee, JJ....

. 2022 ; 140 (3) : 285-289. [pub] 20220721

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025172

Astex Pharmaceuticals Inc Pleasanton CA

Centre Hospitalier Lyon Sud Pierre Bénite France

China Medical University Hospital Taichung Taiwan Republic of China

Copernicus Memorial Hospital Lodz Poland

Coriell Institute for Medical Research Camden NJ

Department of Hematology Medical University of Lodz Lodz Poland

Division of Hematology and Medical Oncology Weill Cornell Medicine Cornell University New York NY

Fakultní Nemocnice Brno Czech Republic

Fakultní Nemocnice Královské Vinohrady Praha Czech Republic

Groupe Hospitalier de la Région Mulhouse Sud Alsace Mulhouse France

Hôpital Saint Louis Paris France

Leukemia Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY

MD Anderson Cancer Center University of Texas Houston TX

Multiprofile Hospital for Active Treatment Sveta Marina EAD Varna Bulgaria

Nagasaki University Hospital Nagasaki Japan

NewYork Presbyterian Hospital New York NY

Ospedale Policlinico San Martino Genova Italy

Princess Margaret Cancer Centre Toronto Canada

Roswell Park Cancer Institute Buffalo NY

Section of Hematology Department of Medicine Yale University New Haven CT

Semmelweis Egyetem Budapest Hungary

Severance Hospital Yonsei University Health System Seoul Republic of Korea

Städtisches Klinikum Braunschweig Braunschweig Germany

Ulm University Hospital Ulm Germany

University of Alberta Hospital Edmonton Canada

Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Warsaw Poland

Yale Cancer Center New Haven CT

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025172
003      
CZ-PrNML
005      
20240516120840.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2022015832 $2 doi
035    __
$a (PubMed)35507690
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zeidan, Amer M $u Section of Hematology, Department of Medicine, Yale University, New Haven, CT $u Yale Cancer Center, New Haven, CT
245    10
$a Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy / $c AM. Zeidan, P. Fenaux, M. Gobbi, J. Mayer, GJ. Roboz, J. Krauter, T. Robak, HM. Kantarjian, J. Novák, WW. Jedrzejczak, X. Thomas, M. Ojeda-Uribe, Y. Miyazaki, YH. Min, SP. Yeh, JM. Brandwein, L. Gercheva, J. Demeter, EA. Griffiths, KWL. Yee, JJ. Issa, JP. Bewersdorf, H. Keer, Y. Hao, M. Azab, H. Döhner
650    _2
$a protinádorové antimetabolity $x terapeutické užití $7 D000964
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a azacytidin $x terapeutické užití $7 D001374
650    _2
$a decitabin $x škodlivé účinky $7 D000077209
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x farmakoterapie $x etiologie $7 D015470
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fenaux, Pierre $u Hôpital Saint Louis, Paris, France
700    1_
$a Gobbi, Marco $u Ospedale Policlinico San Martino, Genova, Italy $1 https://orcid.org/000000030756109X
700    1_
$a Mayer, Jiří $u Fakultní Nemocnice, Brno, Czech Republic
700    1_
$a Roboz, Gail J $u Division of Hematology and Medical Oncology, Weill Cornell Medicine, Cornell University, New York, NY $u NewYork-Presbyterian Hospital, New York, NY $1 https://orcid.org/0000000203843658
700    1_
$a Krauter, Jürgen $u Städtisches Klinikum Braunschweig, Braunschweig, Germany
700    1_
$a Robak, Tadeusz $u Copernicus Memorial Hospital, Lodz, Poland; Department of Hematology, Medical University of Lodz, Lodz, Poland $1 https://orcid.org/0000000234116357
700    1_
$a Kantarjian, Hagop M $u MD Anderson Cancer Center, University of Texas, Houston, TX
700    1_
$a Novák, Jan $u Fakultní Nemocnice Královské Vinohrady, Praha, Czech Republic
700    1_
$a Jedrzejczak, Wieslaw W $u Uniwersyteckie Centrum Kliniczne, Warszawskiego Uniwersytetu Medycznego, Warsaw, Poland $1 https://orcid.org/0000000268133331
700    1_
$a Thomas, Xavier $u Centre Hospitalier Lyon Sud, Pierre-Bénite, France $7 xx0317364
700    1_
$a Ojeda-Uribe, Mario $u Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Mulhouse, France
700    1_
$a Miyazaki, Yasushi $u Nagasaki University Hospital, Nagasaki, Japan
700    1_
$a Min, Yoo Hong $u Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
700    1_
$a Yeh, Su-Peng $u China Medical University Hospital, Taichung, Taiwan, Republic of China
700    1_
$a Brandwein, Joseph M $u University of Alberta Hospital, Edmonton, Canada $1 https://orcid.org/0000000190958789
700    1_
$a Gercheva, Liana $u Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria
700    1_
$a Demeter, Judit $u Semmelweis Egyetem, Budapest, Hungary $1 https://orcid.org/0000000187450757
700    1_
$a Griffiths, Elizabeth A $u Roswell Park Cancer Institute, Buffalo, NY $1 https://orcid.org/0000000202888248
700    1_
$a Yee, Karen W L $u Princess Margaret Cancer Centre, Toronto, Canada $1 https://orcid.org/0000000225729952
700    1_
$a Issa, Jean-Pierre J $u Coriell Institute for Medical Research, Camden, NJ
700    1_
$a Bewersdorf, Jan Philipp $u Section of Hematology, Department of Medicine, Yale University, New Haven, CT $u Yale Cancer Center, New Haven, CT $u Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
700    1_
$a Keer, Harold $u Astex Pharmaceuticals, Inc., Pleasanton, CA; and
700    1_
$a Hao, Yong $u Astex Pharmaceuticals, Inc., Pleasanton, CA; and
700    1_
$a Azab, Mohammad $u Astex Pharmaceuticals, Inc., Pleasanton, CA; and
700    1_
$a Döhner, Hartmut $u Ulm University Hospital, Ulm, Germany $1 https://orcid.org/0000000321165536
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 140, č. 3 (2022), s. 285-289
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35507690 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240516120834 $b ABA008
999    __
$a ok $b bmc $g 1854731 $s 1176462
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 140 $c 3 $d 285-289 $e 20220721 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace